Predictors of Venous Thromboembolism in Patients With Testicular Germ Cell Tumors: A Retrospective Study. (11th June 2021)

• Record Type: Journal Article
• Authors: Abdel-Razeq, Hikmat; Tamimi, Faris; Abdel-Razeq, Rashid; Salah, Samer; Omari, Zaid; Salama, Osama; Abufara, Alaa; Al-Tell, Abdalla; Qahoush, Hanna; Nasman, Ahmad; Taqash, Ayat; Alhalaseh, Yazan; Bater, Rayan
• Is Part Of: Clinical and applied thrombosis/hemostasis. Volume 27(2021)
• Publication Date: 2021-06-11
• Subjects: venous thromboembolism -- VTE -- testicular cancer -- prophylaxis; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 616.13
• DOI: 10.1177/10760296211024756
• Languages: English
• ISSNs: 1076-0296

Abstract

Malignancy, including testicular tumors, significantly increases the risk of venous thromboembolism (VTE). In this study, we search for predictors that may help identify subgroups of patients at higher risk of VTE. Patients with confirmed diagnosis of testicular germ cell tumor and proven VTE were identified. Clinical and pathological features possibly associated with VTE were reviewed. A total of 322 patients, median age (range) 31 (18-76) years were identified. Tumors were mostly non-seminoma (n = 194, 60.2%), node-positive (n = 130, 40.4%) and 58 (18.0%) had metastatic disease at diagnosis. Venous thromboembolism were confirmed in 27 (8.4%) patients; however, rates were significantly higher ( P < 0.001) in patients with node-positive (18.5%), metastatic disease (22.4%), and those with high lactate dehydrogenase (LDH) (21.3%). Rates were also significantly higher among those who received multiple lines of chemotherapy (27.5%) compared to those who received one line (13.8%) or none (<1.0%), P < 0.001. Patients with testicular tumors and high tumor burden, including nodal involvement, high LDH or metastatic disease, and those treated with multiple lines of chemotherapy have significantly higher rates of VTE.